2190 Stock Overview
A medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zylox-Tonbridge Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$11.30 |
| 52 Week High | HK$14.66 |
| 52 Week Low | HK$7.20 |
| Beta | 0.45 |
| 11 Month Change | 11.22% |
| 3 Month Change | 0.53% |
| 1 Year Change | 24.86% |
| 33 Year Change | -71.36% |
| 5 Year Change | n/a |
| Change since IPO | -81.17% |
Recent News & Updates
Recent updates
Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23
Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Shareholder Returns
| 2190 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 2.5% | -2.0% | -3.8% |
| 1Y | 24.9% | -45.8% | -2.3% |
Return vs Industry: 2190 exceeded the Hong Kong Medical Equipment industry which returned -45.8% over the past year.
Return vs Market: 2190 exceeded the Hong Kong Market which returned -2.3% over the past year.
Price Volatility
| 2190 volatility | |
|---|---|
| 2190 Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2190 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2190's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 756 | Jonathon Zhao | www.zyloxtb.com |
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products.
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamentals Summary
| 2190 fundamental statistics | |
|---|---|
| Market cap | HK$3.66b |
| Earnings (TTM) | HK$28.12m |
| Revenue (TTM) | HK$727.57m |
130.0x
P/E Ratio5.0x
P/S RatioIs 2190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2190 income statement (TTM) | |
|---|---|
| Revenue | CN¥663.61m |
| Cost of Revenue | CN¥188.36m |
| Gross Profit | CN¥475.26m |
| Other Expenses | CN¥449.61m |
| Earnings | CN¥25.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.079 |
| Gross Margin | 71.62% |
| Net Profit Margin | 3.86% |
| Debt/Equity Ratio | 2.4% |
How did 2190 perform over the long term?
See historical performance and comparison